A large-scale analysis of alternative splicing reveals a key role of QKI in lung cancer
详细信息 查看全文
- 作者：Fernando J. de Miguela ; b ; Marí ; a J. Pajaresa ; c ; d ; Elena Martí ; nez-Terrobaa ; c ; Daniel Ajonaa ; b ; d ; Xabier Moralese ; Ravi D. Sharmaf ; 1 ; Francisco J. Pardog ; Ana Rouzautb ; d ; e ; Angel Rubiof ; Luis M. Montuengaa ; c ; d ; lmontuenga@unav.es" class="auth_mail" title="E-mail the corresponding author ; Ruben Pioa ; b ; d ; rpio@unav.es" class="auth_mail" title="E-mail the corresponding author
- 关键词：Alternative splicing ; Non-small cell lung cancer ; ESYT2 ; QKI
- 刊名：Molecular Oncology
- 出版年：2016
- 出版时间：November 2016
- 年：2016
- 卷：10
- 期：9
- 页码：1437-1449
- 全文大小：2348 K
文摘
- class="listitem" id="list_ulist0010">
- class="label">•
We have generated an extensive list of differential splicing events in lung cancer.
- class="label">•
The splicing factor QKI is a major regulator of alternative splicing in lung cancer.
- class="label">•
The splicing of ESYT2, a QKI target, regulates actin and endocytosis dynamics.
- class="label">•
QKI protein downregulation is an independent factor for poor prognosis in lung cancer.